Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × BMS-833923 × Dermatologic × Clear all
NCT00670189 2014-08-15

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Bristol-Myers Squibb

Phase 1 Completed
53 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡